Product Information
INSULIN ASPART PENFILL 100 UNIT/ML CARTRIDGE is a generic product labeled by Novo Nordisk, priced at $8.5706 per ML under NDC 73070010215. Its NADAC has been published 325 times since May 20, 2020.
Strength
100 [iU]/mL
Manufacturer
Novo NordiskNDC
73070010215
Classification
Generic
Dosage Form
INJECTION, SOLUTION
Route
INTRAVENOUS; SUBCUTANEOUS
Effective Date
5/20/2026
Active Ingredients
INSULIN ASPARTApproval Type
Biologic (BLA)
FDA Application
BLA020986On Market Since
8/27/2001
Pharmacological Classes
Price Statistics
The NADAC for INSULIN ASPART PENFILL 100 UNIT/ML CARTRIDGE has been published 325 times since May 20, 2020, and over the history we have for it it has declined 50.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $8.5706 per ML |
|---|---|
| All-time high | $17.2973 (Oct 12, 2022) |
| All-time low | $8.5706 (May 20, 2026) |
| 52-week high | $8.6113 |
| 52-week low | $8.5706 |
| Median price | $17.1262 |
| Average price | $13.4068 |
| Largest weekly change | -50.0% (Jan 10, 2024) |
| Weeks tracked | 325 |
| Tracking since | May 20, 2020 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 19% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Novo Nordisk manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
insulin aspart market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Insulin Analog class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of INSULIN ASPART PENFILL 100 UNIT/ML CARTRIDGE?
The current National Average Drug Acquisition Cost (NADAC) for INSULIN ASPART PENFILL 100 UNIT/ML CARTRIDGE, manufactured by Novo Nordisk, is $8.5706 per ML (NDC 73070010215), effective Sep 30, 2026.
How has the price of INSULIN ASPART PENFILL 100 UNIT/ML CARTRIDGE changed over time?
Over the history we have for it, the NADAC for INSULIN ASPART PENFILL 100 UNIT/ML CARTRIDGE has declined 50.2%. It has been tracked across 325 weekly CMS publications since May 20, 2020.
What are the highest and lowest recorded NADAC prices for INSULIN ASPART PENFILL 100 UNIT/ML CARTRIDGE?
Since May 20, 2020, the NADAC for INSULIN ASPART PENFILL 100 UNIT/ML CARTRIDGE has ranged from a low of $8.5706 (May 20, 2026) to a high of $17.2973 (Oct 12, 2022), with a median of $17.1262 per ML.
Are there cheaper alternatives to INSULIN ASPART PENFILL 100 UNIT/ML CARTRIDGE?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, NOVOLOG MIX 70-30 VIAL, is $6.9287 per ML — about 19% below INSULIN ASPART PENFILL 100 UNIT/ML CARTRIDGE.
Who manufactures INSULIN ASPART PENFILL 100 UNIT/ML CARTRIDGE?
INSULIN ASPART PENFILL 100 UNIT/ML CARTRIDGE (NDC 73070010215) is labeled by Novo Nordisk, and CMS classifies it as a generic product.